<DOC>
	<DOCNO>NCT00528450</DOCNO>
	<brief_summary>RATIONALE : Tretinoin may help cancer cell become like normal cell , grow spread slowly . Drugs use chemotherapy , arsenic trioxide idarubicin , work different way stop growth cancer cell , either kill cell stop divide . Giving tretinoin together arsenic trioxide without idarubicin may kill cancer cell . PURPOSE : This phase II trial study well give tretinoin together arsenic trioxide without idarubicin work treat patient acute promyelocytic leukemia .</brief_summary>
	<brief_title>Tretinoin Arsenic Trioxide With Without Idarubicin Treating Patients With Acute Promyelocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine rate molecular remission induction therapy comprise tretinoin ( ATRA ) arsenic trioxide ( ATO ) ( along idarubicin patient leukocytosis ) patient acute promyelocytic leukemia ( APL ) . Secondary - To determine rate clinical complete remission time remission induction therapy . - To determine proportion patient molecular remission course postremission therapy use finding direct number consolidation course ATRA idarubicin administer . - To determine disease-free survival overall survival patient treat regimen . - To determine toxicity treatment regimen , include number length hospitalization , incidence secondary myelodysplastic syndrome acute myeloid leukemia , effect treatment LVEF . - To characterize differentiation APL cell treatment combine ATRA ATO use serial immunophenotyping study peripheral blood bone marrow . - To compare result quantitative real-time reverse transcriptase-polymerase chain reaction ( RT-PCR ) assay perform bone marrow peripheral blood . OUTLINE : - Induction therapy : Patients receive tretinoin orally twice daily arsenic trioxide IV 1-4 hour daily marrow remission document 60 day , whichever come first . Patients leukocytosis ( WBC &gt; 10,000/μL ) also receive idarubicin IV 10-15 minute begin day 2 continue every day 4 dos . Patients achieve clinical complete remission ( CR ) proceed consolidation therapy . If marrow remission achieve 60 day , patient remove study . - Consolidation therapy : - Consolidation course 1 , 2 , 3 : Beginning 3-6 week documentation clinical CR , patient receive consolidation therapy comprise tretinoin orally twice daily 15 day arsenic trioxide IV 1-4 hour daily 5 day week 5 week . Consolidation therapy repeat every 3-6 week 3 course . Patients negative PML-RARα transcript reverse transcriptase-polymerase chain reaction ( RT-PCR ) assay consolidation course 2 proceed maintenance therapy receive consolidation course 3 . Patients negative PML-RARα transcript RT-PCR assay consolidation course 3 , proceed consolidation course 4 follow maintenance therapy . Patients positive PML-RARα transcript RT-PCR assay consolidation course 2 3 proceed consolidation course 4 5 . - Consolidation course 4 : Beginning 3-6 week completion consolidation course 3 , patient receive tretinoin orally twice daily 15 day idarubicin IV 10-15 minute daily 4 day . - Consolidation course 5 : Beginning 3-6 week completion consolidation course 4 , patient receive tretinoin orally twice daily 15 day idarubicin IV 10-15 minute daily 3 day . Patients remain positive PML-RARα transcript 5 course consolidation therapy remove study . Patients negative PML-RARα transcript 5 course consolidation therapy proceed maintenance therapy . - Maintenance therapy : Beginning approximately 3 month completion final consolidation course , patient receive tretinoin orally twice daily 15 day . Treatment repeat every 3 month 2 year . Disease status monitor serial analysis bone marrow peripheral blood sample use RT-PCR PML-RARα mRNA . Patients follow relapse , death , loss follow-up , removal study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Morphologic diagnosis acute promyelocytic leukemia ( APL ) , confirm one following : Demonstration ( 15 ; 17 ) use conventional cytogenetics fluorescence situ hybridization ( FISH ) Positive PMLRARα transcript reverse transcriptasepolymerase chain reaction ( RTPCR ) assay Patients CNS involvement APL eligible PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Creatinine ≤ 2.0 mg/dL creatinine clearance &gt; 60 mL/min Bilirubin &lt; 2.0 mg/dL ( unless attribute Gilbert disease ) Alkaline phosphatase ≤ 2.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 ULN LVEF ≥ 50 % echocardiogram MUGA scan QTc ≤ 500 msec baseline ECG Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 4 month completion study treatment No active serious infection control antibiotic No concurrent active malignancy require immediate therapy No clinically significant cardiac disease ( New York Heart Association class III IV heart disease ) , include chronic arrhythmia No pulmonary disease No serious lifethreatening condition deem unacceptable principal investigator PRIOR CONCURRENT THERAPY : No prior treatment APL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
</DOC>